Quality evaluation and comparison of immunoglobulin prepared by two various methods of human plasma fractionation

Document Type : Research Paper

Authors

1 Immunology Department, Semnan University of Medical Sciences, Semnan, Iran

2 Blood Transfusion Research center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

3 Pishro Tashkhis Fardavar Company, Tehran, Iran

4 IGT Lab. CCK, R8, Karolinska University Hospital, Solna, 171-76 Stockholm, Sweden

5 Iranian Blood Research and Fractionation Company, 1449613111, Tehran, Iran

10.22034/ijps.2019.104507.1535

Abstract

Based on European Pharmacopeia, there are some features which should be measured for any intravenous immunoglobulins prior to final release of the product. The most critical ones are the level of prekallikrein and anti-complementary activity in final formulation. For all commercial products, the national reference laboratory is prone to conduct such tests and there is no local report on quality control tests done on the products derived from Iranian human plasma. The study is to measure and control the international requirements such as prekallikrein count and anti-complementary activity for human intravenous immunoglobulins manufactured by local developed process in Iran in pilot scale. IgG-rich fraction was obtained by two fractionation methods. Cryoprecipitate was separated from tested fresh frozen plasma in both methods. In method I, for the next steps, fraction I paste, fraction II+III paste, and at the end, the fraction II paste were precipitated. In method II, the fraction I+II+III paste was simultaneously precipitated followed by deriving the fraction II paste. The paste obtained by both methods was separately subjected to the purification processes using anion and cation exchange chromatography followed by gel filtration and activity level of Prekallikrein in addition to anti-complement activity were compared with other laboratory evaluations. No difference was illustrated between protein and albumin content, pH, and conductivity of the two products. The fraction II paste obtained from both methods, was measured and compared with each other. The IgG yield compared to the primary plasma was calculated as 4.6 and 4.3 g for the aforementioned methods respectively. The absence of impurities was determined by a strong IgG bond in electrophoresis while by HPLC, the dimer/ monomer content was measured more than 99% and the polymer/ aggregate was less than 1%. The amount of prekallikrein and total anti-coagulant activity met the European Pharmacopoeia requirements for both methods.

Keywords

References

[1] Cohn EJ, Oncley JL, Strong LE, Hughes WL and Armstrong SH. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J. Clin. Investing. (1944) 23 (4): 417-32.
[2] Stiehm ER, Vaerman JP and Fudenberg HH. Plasma infusions in immunologic deficiency states: metabolic and therapeutic studies. Blood (1966) 28 (6): 918-37.
[3] Barandun S, Kistler P, Jeunet F and Isliker H. Intravenous administration of human gamma-globulin. Vox. Sang. (1962) 7: 157-74.
[4] Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ and Nelson J. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin. Immunol. Immunopathol. (1982) 22 (1): 60-7.
[5] Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boule A, Cunningham-Rundles S and O'Malley J. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann. Intern. Med. (1984) 101(4): 435-9.
[6] Buckley RH and Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N. Engl. J. Med. (1991) 325 (2): 110-7.
[7] Milgrom H. Shortage of intravenous immunoglobulin. Ann. Allergy. Asthma. Immunol. (1998) 81(2): 97-100.
[8] Farrugia A and Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus. Med. (2001) 11(2): 63-74.
[9] Burnouf T. Chromatography in plasma fractionation: benefits and future trends. J. Chromatogr, B, Biomed. Sci. Appl. (1995) 664 (1): 3-15.
[10] Shin IS, Shim YB, Hong CM, Koh HC, Lee SH and Hong SH. An improved, reliable and practical kinetic assay for the detection of prekallikrein activator in blood products. Arch. Pharm. Res. (2002) 25(4): 505-10.
[11] Kaplan AP, Joseph K and Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy. Clin. Immunol. (2002) 109 (2): 195-209.
[12] European Pharmacopoeia: Human normal immunoglobulin for intravenous administration. European Pharmacopoeia 6.3, monograph 2.6.17. 4166–8. Council of Europe, Strasbourg Cedex, France.
[13] Cheraghali AM and Abolghasemi H. Improving availability and affordability of plasma-derived medicines. Biologicals. (2010) 38 (1):81-6.
[14] Burnouf T. Plasma fractionation. ISBT Vox Sang. (2012) 7: 62–67.
[15] Tanaka K, Sawatani E, Dias G, Shigueoka E, Campos T, Nakao H and Arashiro F. High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. Braz. J. Med. Biol. Res. (2000) 33: 27-30.
[16] Lebing W, Remington K, Schreiner C and Paul HI. Properties of a new intravenous immunoglobulin (IGIV‐C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang. (2003) 84: 193-201.
[17] Sisti A, Vitali M, Manfredi M and Zarzur J. Preparation of lyophilized and liquid intravenous immunoglobulin G: development and scale‐up. Vox Sang. (2001) 80: 216-24.
[18] Pierce LR and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. (2003) 17(4):241-51.
[19] Nezlin R. Interactions between immunoglobulin G molecules. Immunol. Lett. (2010) 132(1-2):1-5.
Iranian Journal of Pharmaceutical Sciences
Volume 16, Issue 3
July 2020
Pages 81-94

Files

Share

How to cite

Statistics